Gain Therapeutics Inc. (GANX) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

The Roarable RQD rating is 41 out of 100, a letter grade of D-, with the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow" (). Across its five pillars:

• Fundamental Cash Engine: 7 / 20. The rating cites ROIC of -35% and FCF yield of 0% (). For a prospective investor, this means the company is not currently generating returns on invested capital or free cash flow; the valuation case rests on future outcomes rather than current earnings power.
• Whale 13F Flow: 3 / 20. This pillar, the weakest, reflects institutional accumulation and options positioning (). The source data supplies no holder detail, so the score signals weak institutional support without showing its underlying positions.
• Insider Conviction: 7 / 20. This pillar reflects SEC Form 4 and Congressional PTR cluster flow (). The holders section contains no detail, so the investor cannot verify the basis for this score.
• Macro Regime Fit: 11 / 20. The rating cites Beta of 1.0 and sector sensitivity (). A beta of 1.0 means the stock is rated as moving in line with the market; the score reflects moderate, not strong, regime alignment.
• Forensic Balance Sheet: 13 / 20. The rating cites Altman Z of 2.5, Piotroski F of 4/9, and Debt/Equity of 0.02 (). This is the strongest pillar, indicating low leverage and a moderate financial-health profile, though the Piotroski score is below midpoint.

Investor implications. The upside case depends on whether the company converts its cash position into value-creating outcomes, since current returns are negative. The valuation tradeoff is that the market cap of $51.9M sits against a 52-week range of $1.11 to $4.34 and a current price of $1.19 (per the Snapshot data); the stock trades near the bottom of its range. Low debt supports balance-sheet resilience, but weak flow pillars mean sentiment and capital access remain key risks.

Gain Therapeutics Inc. (GANX) is a NASDAQ-listed issuer. It operates in the Health Care sector, in the Biotechnology: Pharmaceutical Preparations industry. The FY 2025 and FY 2024 revenue are each —, and FY 2023 revenue is $0.1M ().

And market data, the company reported operating losses in each period shown, and gross, operating, and net margins are each 0%. ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 4/9 (). Cash rose from $10.4M in FY 2024 to $20.8M in FY 2025, while debt held at $0.3M in both years (). The Debt/Equity ratio is 0.02 ().

• 🐂 Primary Bull Case: Low leverage (Debt/Equity 0.02) and cash rising to $20.8M in FY 2025 give the balance sheet room to fund operations. With Fundamental Cash Engine at 7/20 (ROIC -35.0%, FCF yield —) and Institutional Whale Flow at 3/20, sustained execution supports upside toward the top of the $1.11 – $4.34 52-week range.
• 🐻 Primary Bear Case: Operating losses of -$18.7M against zero revenue and ROIC of -35% mean the company is not yet producing returns on the capital it consumes. Investors must weigh current valuation against — operating margins and a 1.00 macro beta if sector demand softens.

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), GANX carries a macro regime beta of 1.00 and gross margin of —.

• Key Question #1: What is the basis for the "trial data" referenced in the BTIG headline, and what does the data show?
• Key Question #2: What are the reasons behind the FY 2025 cash increase to $20.8M, and what is the cash runway at the current FCF burn rate?
• Key Question #3: How sensitive is GANX's — gross margin and equity valuation to Health Care demand cycles and macro interest-rate shifts (Beta 1.00)?